Broncho-munal P, capsules 3.5mg 10 pcs

ATX code: L03AX.

Pharmacotherapeutic group:immunostimulant.
Nosological classification: ICD-10

Pharmacological properties

Pharmacodynamics
The drug Broncho-Munal® P has an immune stimulating effect, increasing immunity against respiratory tract infections.
In patients receiving the drug Broncho-Munal ® P, the protective properties of the body against bacteria and viruses are enhanced.
After taking the capsule bacterial lysate accumulates in the peer plaques of the mucous membrane of the gastrointestinal tract, particularly located in the small intestine. The antigen-presenting cells in the peyer plaques are activated by the bacterial lysate and subsequently stimulate other cell types (B-lymphocytes) responsible for specific immunity. This leads to an increase in the number of circulating B-lymphocytes leading to increased production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory mucosa and salivary glands.

The drug also affects non-specific immunity by stimulating leukocytes, characterized by increase of myeloid and lymphoid cells number and selective increase of receptors expression on their surface.

Clinically Broncho-Munal® P reduces the frequency of acute respiratory tract infections, reduces the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, as well as increases the body’s resistance to infections of the respiratory system. It also reduces the need to use other medicines, especially antibiotics.

Indications

Laryngitis, sinusitis, otitis, runny nose (rhinitis), sore throat, respiratory tract infections, pharyngitis, tonsillitis, bronchitis Broncho-Munal® P is used in children aged 6 months to 12 years:
– in the treatment of acute respiratory tract infections;
– for the prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis.

Active ingredient

Bacterial lysates

Composition

1 capsule contains:

Active substance:
Bacterial lysates as standardized bacterial lyophilisate (OM-85) (OM-Pharma, Switzerland) – 3.500 mg:
Haemophilus influenzae
Streptococcus pneumoniae
Streptococcus viridans
Streptococcus pyogenes
Klebsiella pneumoniae
Klebsiella ozaenae
Staphylococcus aureus
Moraxella catarrhalis

Associates:
propyl gallate (anhydrous)
sodium glutamate (anhydrous)
mannitol
magnesium stearate
pregelatinized starch
mannitol
Capsule shell:
indigotine E132
titanium dioxide E171
gelatin

How to take, the dosage

Children from 6 months to 12 years. The drug is taken 1 capsule daily in the morning, on an empty stomach, 30 minutes before a meal. For children under 3 years of age, or if the child is difficult to swallow the capsule, it should be opened, the contents mixed with a small amount of liquid (tea, milk or juice).

– For prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis the drug is used in three courses of 10 days each, the interval between courses is 20 days.

In combination therapy of acute respiratory tract infections the drug is used until relief of symptoms, but not less than 10 days. In case of antibiotic therapy Broncho-Munal® P should be taken in combination with antibiotics from the beginning of treatment.

The next 2 months the preparation can be used prophylactically: by courses of 10 days, the interval between the courses is 20 days.

Interaction

The drug can be used simultaneously with other medications, including antibiotics.

Special Instructions

To avoid overdose, Broncho-Munal® capsules 7 mg should not be used in children from 6 months to 12 years of age intended for adults. Hypersensitivity reactions to the drug may occur. In case of persisting gastrointestinal disorders, skin reactions, respiratory disorders or other symptoms of intolerance to the drug, discontinue the drug and consult a physician.

Synopsis

Capsules: Hard gelatin capsules size #3 with a white opaque body and blue opaque cap.
Capsule contents: light beige powder.

Contraindications

– Hypersensitivity to the drug components;
– Pregnancy;
– Breast-feeding period;
– Childhood under 6 months.

Side effects

Broncho-Munal® P is usually well tolerated. Most adverse reactions are classified into the general category with moderate to moderate severity. The most common side effects are gastrointestinal disorders, skin reactions and respiratory disorders.

According to the World Health Organization (WHO) adverse effects are classified according to their frequency of development as follows:
– very frequently (≥ 1/10);
– frequently (≥ 1/100, < 1/10);
– infrequently (≥ 1/1000, < 1/100);
– rarely (≥ 1/10000, < 1/1000);
– very rarely (< 1/10000);
– frequency is unknown (frequency of the phenomena cannot be determined on the basis of available data).

Gastrointestinal tract disorders:
– often: diarrhea, abdominal pain;
– frequency unknown: nausea, vomiting.

Respiratory system disorders:
– often: cough;
– infrequently: shortness of breath.

Skin and subcutaneous tissue disorders:
– often: rash;
– frequency unknown: urticaria, angioedema.

Immune system disorders:
– infrequent: hypersensitivity reactions (erythematous rash, generalized rash, erythema, edema, eyelid edema, facial edema, peripheral edema, swelling, swollen face, itching, generalized itching).

Nervous system disorders:
– frequency unknown: headache.

General disorders:
– frequency unknown: fever, fatigue.

Overdose

There are no reports of intoxication due to drug overdose. The nature of Broncho-Munal® P and the results of its toxicity studies in animals indicate that overdose is unlikely.

Similarities

Broncho-munal, IRS-19, Imudon, Ismigen, For sore throat and ARVI